Physician profile
Renny Abraham
NPI 1811995673
$5,416.80
in general payments reported to CMS, 2019-2025
45 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $230 · 2021: $516 · 2022: $927 · 2023: $1,224 · 2024: $1,203 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.54 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.65 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $776.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $670.30 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $523.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $292.01 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $208.82 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $192.03 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Cranial Technologies, INC | $164.28 | 2019-2025 | Doc Band |
| Amgen INC. | $134.75 | 2019-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $132.35 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $106.06 | 2022-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $102.22 | 2022 | |
| Exact Sciences Corporation | $100.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $96.40 | 2023-2024 | Quviviq |
| Corium, LLC | $82.31 | 2022-2024 | Azstarys |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renny Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.